Loading stock data…
RNAZ
$7.83-0.38 (-4.57%)
Market ClosedLast close May 1
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TransCode Therapeutics, Inc. in the Healthcare sector is trading at $7.83. The stock is currently near its 52-week low of $6.08, remaining 21.1% below its 200-day moving average. Technical signals show oversold RSI of 22 and bearish MACD signal, explaining why RNAZ maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 22) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.83
Potential Upside
5%
Whystock Fair Value$8.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.88M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1068.05%
Volume
Today's trading volume
5,116
Recent News
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index and the Health Car
Sector Update: Health Care Stocks Advance Wednesday Afternoon
Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Hea
TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences
TransCode Therapeutics (RNAZ) said Wednesday it has agreed to buy biotechnology immuno-oncology comp
Wall Street Set to Open Higher Wednesday; Dow Rises on Japan Trade Deal
US stocks look set to open higher in Wednesday's trading session after the US announced a trade deal